Pre-treatment maximal oesophageal wall thickness is independently associated with response to chemoradiotherapy in patients with T3-4 oesophageal squamous cell carcinoma

European Journal of Cardio-thoracic Surgery

Volumn 42, Issue 6, 2012, Pages 958-964

  Li, Shau Hsuan ^a   Rau, Kun Ming ^a   Lu, Hung I ^a   Wang, Yu Ming ^a   Tien, Wan Yu ^a   Liang, Jiun Lung ^a   Lin, Wei Che ^a  

^a CHANG GUNG UNIVERSITY COLLEGE OF MEDICINE   (Taiwan)

Author keywords

Chemoradiotherapy; Computed tomography; Maximal oesophageal wall thickness; Oesophageal squamous cell carcinoma; Pathologically complete response

Indexed keywords

CISPLATIN; FLUOROURACIL;

ADULT; ADVANCED CANCER; AGED; ARTICLE; BLOOD VESSEL PARAMETERS; CANCER ADJUVANT THERAPY; CANCER LOCALIZATION; CANCER PROGNOSIS; CANCER STAGING; CANCER SURGERY; CANCER SURVIVAL; CHEMORADIOTHERAPY; COMPUTER ASSISTED RADIOTHERAPY; COMPUTER ASSISTED TOMOGRAPHY; DISEASE FREE SURVIVAL; DISEASE SPECIFIC SURVIVAL; ESOPHAGEAL SQUAMOUS CELL CARCINOMA; ESOPHAGEAL WALL THICKNESS; ESOPHAGUS RESECTION; FEMALE; HUMAN; LYMPH NODE DISSECTION; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RETROSPECTIVE STUDY; TREATMENT OUTCOME; TREATMENT RESPONSE;

ADULT; AGED; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, SQUAMOUS CELL; CHEMORADIOTHERAPY, ADJUVANT; CISPLATIN; ESOPHAGEAL NEOPLASMS; ESOPHAGECTOMY; ESOPHAGUS; FEMALE; FLUOROURACIL; FOLLOW-UP STUDIES; HUMANS; LOGISTIC MODELS; MALE; MIDDLE AGED; MULTIDETECTOR COMPUTED TOMOGRAPHY; NEOADJUVANT THERAPY; NEOPLASM STAGING; RADIOTHERAPY, CONFORMAL; RETROSPECTIVE STUDIES; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 84873110243     PISSN: 10107940     EISSN: 1873734X     Source Type: Journal    
DOI: 10.1093/ejcts/ezs136     Document Type: Article

References (25)

1. Siewert JR, Stein HJ, Feith M, Bruecher BL, Bartels H, Fink U. Histologic tumor type is an independent prognostic parameter in esophageal cancer: lessons from more than 1,000 consecutive resections at a single center in the Western world. Ann Surg 2001;234:360-67; discussion 368-9.
2. Sherman CA, Turrisi AT, Wallace MB, Reed CE. Locally advanced esophageal cancer. Curr Treat Options Oncol 2002;3:475-85.
3. Stahl M, Stuschke M, Lehmann N, Meyer HJ, Walz MK, Seeber S et al. Chemoradiation with and without surgery in patients with locally advanced squamous cell carcinoma of the esophagus. J Clin Oncol 2005; 23:2310-7.
4. Bedenne L, Michel P, Bouche O, Milan C, Mariette C, Conroy T et al. Chemoradiation followed by surgery compared with chemoradiation alone in squamous cancer of the esophagus: FFCD 9102. J Clin Oncol 2007;25:1160-8.
5. Donington JS, Miller DL, Allen MS, Deschamps C, Nichols FC III, Pairolero PC. Tumor response to induction chemoradiation: influence on survival after esophagectomy. Eur J Cardiothorac Surg 2003;24:631-6; discussion 636-7.
6. Jones DR, Detterbeck FC, Egan TM, Parker LA Jr, Bernard SA, Tepper JE. Induction chemoradiotherapy followed by esophagectomy in patients with carcinoma of the esophagus. Ann Thorac Surg 1997;64:185-91; discussion 191-2.
7. Steyerberg EW, Neville BA, Koppert LB, Lemmens VE, Tilanus HW, Coebergh JW et al. Surgical mortality in patients with esophageal cancer: development and validation of a simple risk score. J Clin Oncol 2006;24: 4277-84.
8. Hagry O, Coosemans W, De Leyn P, Nafteux P, Van Raemdonck D, Van Cutsem E et al. Effects of preoperative chemoradiotherapy on postsurgical morbidity and mortality in cT3-4 +/- cM1lymph cancer of the oesophagus and gastro-oesophageal junction. Eur J Cardiothorac Surg 2003;24:179-86; discussion 186.
9. D'Journo XB, Michelet P, Marin V, Diesnis I, Blayac D, Doddoli C et al. An early inflammatory response to oesophagectomy predicts the occurrence of pulmonary complications. Eur J Cardiothorac Surg 2010;37: 1144-51.
10. Swisher SG, Maish M, Erasmus JJ, Correa AM, Ajani JA, Bresalier R et al. Utility of PET, CT, and EUS to identify pathologic responders in esophageal cancer. Ann Thorac Surg 2004;78:1152-60; discussion 1152-60.
11. Rohatgi PR, Swisher SG, Correa AM, Wu TT, Liao Z, Komaki R et al. Histologic subtypes as determinants of outcome in esophageal carcinoma patients with pathologic complete response after preoperative chemoradiotherapy. Cancer 2006;106:552-8.
12. Rizk NP, Seshan VE, Bains MS, Ilson DH, Minsky BD, Tang L et al. Prognostic factors after combined modality treatment of squamous cell carcinoma of the esophagus. J Thorac Oncol 2007;2:1117-23.
13. Dresner SM, Wayman J, Shenfine J, Harris A, Hayes N, Griffin SM. Pattern of recurrence following subtotal oesophagectomy with two field lymphadenectomy. Br J Surg 2000;87:362-73.
14. Schneider BJ, Urba SG. Preoperative chemoradiation for the treatment of locoregional esophageal cancer: the standard of care? Semin Radiat Oncol 2007;17:45-52.
15. Berger AC, Farma J, Scott WJ, Freedman G, Weiner L, Cheng JD et al. Complete response to neoadjuvant chemoradiotherapy in esophageal carcinoma is associated with significantly improved survival. J Clin Oncol 2005;23:4330-7.
16. Siewert JR, Ott K. Are squamous and adenocarcinomas of the esophagus the same disease? Semin Radiat Oncol 2007;17:38-44.
17. Ichimiya Y, Fuwa N, Kamata M, Kodaira T, Furutani K, Tachibana H et al. Treatment results of stage I oral tongue cancer with definitive radiotherapy. Oral Oncol 2005;41:520-5.
18. Plataniotis GA, Theofanopoulou ME, Kalogera-Fountzila A, Haritanti A, Ciuleanou E, Ghilezan N et al. Prognostic impact of tumor volumetry in patients with locally advanced head-and-neck carcinoma (nonnasopharyngeal) treated by radiotherapy alone or combined radiochemotherapy in a randomized trial. Int J Radiat Oncol Biol Phys 2004;59: 1018-26.
19. Soliman H, Cheung P, Yeung L, Poon I, Balogh J, Barbera L et al. Accelerated hypofractionated radiotherapy for early-stage non-small-cell lung cancer: long-term results. Int J Radiat Oncol Biol Phys 2011;79: 459-65.
20. Lee DW, Kim YT, Kim JH, Kim S, Kim SW, Nam EJ et al. Clinical significance of tumor volume and lymph node involvement assessed by MRI in stage IIB cervical cancer patients treated with concurrent chemoradiation therapy. J Gynecol Oncol 2010;21:18-23.
21. Rice TW, Rusch VW, Ishwaran H, Blackstone EH. Cancer of the esophagus and esophagogastric junction: data-driven staging for the seventh edition of the American Joint Committee on Cancer/International Union against Cancer Cancer Staging Manuals. Cancer 2010;116: 3763-73.
22. Barbour AP, Jones M, Gonen M, Gotley DC, Thomas J, Thomson DB et al. Refining esophageal cancer staging after neoadjuvant therapy: importance of treatment response. Ann Surg Oncol 2008;15: 2894-902.
23. Hsu CP, Chen CY, Hsia JY, Shai SE. Prediction of prognosis by the extent of lymph node involvement in squamous cell carcinoma of the thoracic esophagus. Eur J Cardiothorac Surg 2001;19:10-3.
24. Liu J, Xie X, Zhou C, Peng S, Rao D, Fu J. Which factors are associated with actual 5-year survival of oesophageal squamous cell carcinoma? Eur J Cardiothorac Surg 2012;41:e7-e11.
25. Tio TL, Cohen P, Coene PP, Udding J, den Hartog Jager FC, Tytgat GN. Endosonography and computed tomography of esophageal carcinoma. Preoperative classification compared to the new (1987) TNM system. Gastroenterology 1989;96:1478-86.